Clinical Research

Clinical Research

Paediatric Hepatic International Tumour Trial (PHITT)
Site Principal Investigator: Dr. Soh Shui Yen
SIOP Renal Tumour Study Group (RTSG) (UMBRELLA Protocol)
Site Principal Investigator: Dr. Prasad Iyer
DAY101 in Paediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advanced Solid Tumours (FIREFLY-1)
(ClinicalTrials.gov Identifier: NCT04775485)
Site Principal Investigator: Dr. Enrica Tan
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
(ClinicalTrials.gov Identifier: NCT05566795)
Site Principal Investigator: Dr. Enrica Tan
Repotrectinib in Paediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
(ClinicalTrials.gov Identifier: NCT04094610)
Site Principal Investigator: Dr. Soh Shui Yen
Comprehensive Genomic Profiling of Paediatric Brain and Solid Tumours (SPONC18B1)
Site Principal Investigator: Dr. Mya Soe Nwe
Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in paediatric patients with relapsed or refractory neuroblastoma and other solid tumours
(ClinicalTrials.gov Identifier: NCT05429502)
Site Principal Investigator: Dr. Soh Shui Yen

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy (SHCELL18P1)
(ClinicalTrials.gov Identifier: NCT05648019)
Principal Investigator: Dr. Soh Shui Yen
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T-cell Therapy
(ClinicalTrials.gov Identifier: NCT05429905)
Principal Investigator: Dr. Michaela Seng
Novel Adoptive Cellular Therapy with SARS-CoV-2 Specific T cells in Patients with Severe COVID-19
(ClinicalTrials.gov Identifier: NCT04351659)
Principal Investigator: Dr. Michaela Seng

Malaysia – Singapore Acute Lymphoblastic Leukaemia – Seq 2020
(ClinicalTrials.gov Identifier: pending)
Site Principal Investigator: A/Prof. Tan Ah Moy
Asia Down Syndrome – Acute Lymphoblastic Leukaemia (DS-ALL) 2016
(ClinicalTrials.gov Identifier: NCT03286634)
Site Principal Investigator: A/Prof. Tan Ah Moy
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory ALL
(ClinicalTrials.gov Identifier: NCT02303821)
Site Principal Investigator: Dr. Prasad Iyer
BH3 Profiling on ALL and AML Blasts to Direct Leukemia and Lymphoma Treatment
Site Principal Investigator: Dr. Prasad Iyer

PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Patients (PUP) With Severe Haemophilia A
(ClinicalTrials.gov Identifier: NCT02615691)
Principal Investigator: Dr. Joyce Lam
MUSFIH-PRO
Principal Investigator: Dr. Joyce Lam

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
(ClinicalTrials.gov Identifier: NCT02798471)
Site Principal Investigator: Dr. Joyce Lam
Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network
Site Principal Investigator: Dr. Joyce Lam
International Epidemiological Study of Neonatal Purpura Fulminans
Site Principal Investigator: Dr. Joyce Lam
International Paediatric Thrombosis Network
Site Principal Investigator: Dr. Joyce Lam

The research arm of the Children's Cancer Foundation (CCF) Psychosocial Supportive Care Programme (PSCP) aims to explore and develop innovative interventions to address the psychosocial needs of children with cancer and their families in Singapore. Our ongoing research ensures that our support services are up-to-date with the best clinical practices, so that our patients and families receive the best possible care.

Basic and translational research

Expand All

About the Principle Investigator (PI):

Asst Prof Amos Loh Hong Pheng

Senior Consultant

Chairman of the Division of Surgery, Department of Paediatric Surgery, KK Women's and Children's Hospital

Dr Amos Loh is Chairman of the Division of Surgery and Senior Consultant at the Department of Paediatric Surgery, KK Women's and Children's Hospital, and Assistant Professor at the Duke NUS Medical School. He is also Principal Investigator of the VIVA-KKH Paediatric Solid Tumour Research Laboratory and Chairman of the VIVA-KKH Paediatric Brain and Solid Tumour Programme, and has a clinical practice and academic research focus in paediatric surgical oncology and childhood solid tumours.

Dr Loh obtained his medical degree from the National University of Singapore in 2002. He trained subsequently in general and paediatric surgery and was awarded the Academy of Medicine Singapore College of Surgeons Gold Medal in paediatric surgery. He pursued a paediatric surgical oncology fellowship and a research fellowship at St Jude Children's Research Hospital, for which he was awarded a National Medical Research Council research training award.

His academic interests are in clinical and translational research in paediatric solid tumours, in particular, patient-derived preclinical models of paediatric solid tumors, and novel biomarker discovery for prognostication and therapeutic stratification.

About the BST Laboratory:

Using a translational research pipeline, we adopt a targeted approach to advance scientific findings from basic, to pre-clinical and early clinical development, and on to early phase clinical trials, for various paediatric brain and solid tumours. Given the wide variety of tumour types, the Programme has adopted a special focus on development of personalised medical management strategies through individualized molecular and phenotypic tests.

Current Initiatives:

Modeling, Analysis and Translational Therapeutics for Tumours of Childhood (MAT3CH)

This platform develops orthotopic patient-derived xenografts (PDX) and in vitro cell line models of paediatric brain and solid tumours, in order to facilitate molecular characterization and evaluation of novel therapies for these diseases. This programme facilitates the molecular characterization of paediatric solid tumours in Asian children for the identification of pathogenic molecular aberrations, comparisons of inter-population variations, and in-vivo evaluation of novel agents for translation into early-phase human trials.

BST programme achievements:

(a) Translational research

Programme has published a total of 81 publications and peer-reviewed journals and 71 presentations as at end 2021.
Programme has developed and launched 5 key new lab-developed tests specially catered for paediatric brain and solid tumours.
Through local and international collaborations, resource hubs have been launched to share preclinical models of childhood brain and solid tumours that have been established under the Programme’s MAT3CH project since 2015.

Professor Leung Wing Hang
Director, KKH Children’s Blood and Cancer Center
Senior Consultant, Haematology/Oncology Service, Division of Medicine, KK Women’ and Children’s Hospital

Professor Leung is the Director of the Children's Blood and Cancer Centre and a Senior Consultant at KK Women's and Children's Hospital, part of SingHealth. He also serves as a Professor at Duke-NUS Medical School.

Previously, Professor Leung was a faculty member at Johns Hopkins University, where he held the position of Chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital. He also served as the Chair of the Department of Paediatrics at the University of Hong Kong. He was honored with the title of Distinguished Professor and Chair of the SingHealth Duke-NUS Tan Cheng Lim – CCF Professorship in Paediatric Oncology.

Throughout his career, Professor Leung has held several significant appointments, including Lead for SingHealth Transplant Research, Director of the Paediatric Bone Marrow Transplantation and Cellular Therapy Centre, and Director of Research at the SingHealth Duke-NUS Transplant Centre.

His research interests focus on the biology of human natural killer cells and T-memory cells, with a particular emphasis on their clinical applications in the treatment of cancer, blood disorders, immune system conditions, and infectious diseases.

About the BMTCT Laboratory:

The KKH BMTCT research laboratory conducts basic science investigations and generates preclinical and correlative research which will be of immediate translational use in the clinics. Our laboratory is situated in the Discovery Tower at Academia, which houses SingHealth’s research laboratories and experimental animal facilities, within the vicinity of Duke-NUS Medical School. The vision is for a seamless circuit from innovation and discovery to animal in vivo studies and finally to the bedside, with robust correlative platforms and generating more areas of research. We aim to increase collaborations and exchanges with other centres to advance transplantation and cellular therapy in Singapore and beyond.

Some of the Programme's collaborations:

External: NCCS Cancer Discovery Hub and NCCS Laboratory of Cell Therapy and Cancer Vaccines, Health Sciences Authority, Cell Therapy Facility, NUH Stem Cell Laboratory
Internal: Brain and Solid Tumour Programme

Laboratory Journals:

W Leung, TG Soh, YC Linn, JGH Low, JS Loh, M Chan, WJ Chng, LP Koh, ML Poon, KP Ng, CH Kuik, TT Tan, LK Tan, MS Seng. Rapid production of clinical-grade SARS CoV-2 specific T cells. Adv Cell Gene Ther. 2020 Oct; 3(4):e101.
DOI:10.1002/acg2.101 PMID 32838213

For more information, visit our Blood and Marrow Tansplant and Cellular Therapy Centre via this Link